Q-omics provides the consensus-scored C22orf39 profile across patient tissues and cancer cell-line models. C22orf39 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, C22orf39 is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, C22orf39 RNA expression shows 20,646 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UCEC, THCA, and ACC as cancer lineages where C22orf39 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C22orf39 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C22orf39 survival associations across molecular data types. C22orf39 RNA expression shows survival associations in the most cancer types (24), followed by mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C22orf39 RNA expression–survival associations across cancer types. High C22orf39 expression shows unfavorable associations in ACC, LIHC and UVM, but favorable associations in UCEC, THYM and LGG. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for C22orf39 RNA expression.
This table summarizes C22orf39 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for C22orf39. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C22orf39 shows lower tumor expression in THCA, LUAD, BLCA, LUSC and KICH and higher tumor expression in LIHC. The THCA box plot shows higher C22orf39 RNA expression in normal versus tumor tissue (log2 FC = −1.137, t-test p < 0.001).
This table shows molecular features associated with C22orf39 in patient tissues and cancer cell lines. In patient samples, C22orf39 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, C22orf39 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
